Načítá se...
Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
INTRODUCTION: Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing/remitting course with transmural inflammation of potentially any section of the digestive tract. Certolizumab pegol (CZP) is a pegylated Fc-free Fab’ fragment of a humanized anti-TNF-alfa monoclon...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2007
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3012434/ https://ncbi.nlm.nih.gov/pubmed/21221187 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|